Ftse Mib
34.683,85
-0,43%
DAX
18.557,27
-0,48%
S&P 500
5.374,50
0,40%
NASDAQ
17.208,80
0,21%
Bitcoin
70.411,53
-0,50%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Invivyd Inc (IVVD) Invivyd Inc (IVVD) Notizie

IVVD

Invivyd (IVVD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IVVD
DataOraFonteTitoloSimboloCompagnia
06/06/202422:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc
06/06/202422:57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc
03/06/202422:01GlobeNewswire Inc.Invivyd to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:IVVDInvivyd Inc
31/05/202413:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
31/05/202413:05GlobeNewswire Inc.Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for SerialNASDAQ:IVVDInvivyd Inc
31/05/202413:00GlobeNewswire Inc.Invivyd Announces the Appointment of Timothy Lee as Chief Commercial OfficerNASDAQ:IVVDInvivyd Inc
29/05/202413:00GlobeNewswire Inc.Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)NASDAQ:IVVDInvivyd Inc
22/05/202413:00GlobeNewswire Inc.Invivyd Elects Two New Independent Members to its Board of DirectorsNASDAQ:IVVDInvivyd Inc
16/05/202422:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IVVDInvivyd Inc
13/05/202422:01GlobeNewswire Inc.Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:IVVDInvivyd Inc
09/05/202422:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IVVDInvivyd Inc
09/05/202422:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IVVDInvivyd Inc
09/05/202422:01GlobeNewswire Inc.Invivyd Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
07/05/202413:30GlobeNewswire Inc.Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA FeedbackNASDAQ:IVVDInvivyd Inc
02/05/202423:13GlobeNewswire Inc.Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business HighlightsNASDAQ:IVVDInvivyd Inc
30/04/202413:30GlobeNewswire Inc.Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash PositionNASDAQ:IVVDInvivyd Inc
15/04/202413:30GlobeNewswire Inc.Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™NASDAQ:IVVDInvivyd Inc
12/04/202413:30GlobeNewswire Inc.Invivyd Announces CEO TransitionNASDAQ:IVVDInvivyd Inc
04/04/202422:01GlobeNewswire Inc.Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionNASDAQ:IVVDInvivyd Inc
28/03/202412:00GlobeNewswire Inc.Invivyd Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
22/03/202420:28GlobeNewswire Inc.Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical TrialNASDAQ:IVVDInvivyd Inc
22/03/202420:04GlobeNewswire Inc.Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19NASDAQ:IVVDInvivyd Inc
12/02/202422:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IVVDInvivyd Inc
09/02/202422:47Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IVVDInvivyd Inc
05/02/202422:02GlobeNewswire Inc.Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:IVVDInvivyd Inc
03/01/202413:00GlobeNewswire Inc.Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and AdolescentsNASDAQ:IVVDInvivyd Inc
22/12/202322:51Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IVVDInvivyd Inc
18/12/202313:00GlobeNewswire Inc.Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19NASDAQ:IVVDInvivyd Inc
09/11/202322:01GlobeNewswire Inc.Invivyd Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
02/11/202321:01GlobeNewswire Inc.Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:IVVDInvivyd Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IVVD

La tua Cronologia

USOTC
CARFP
Carlyle Credit Income (GM)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network